Literature DB >> 20944133

Differential expression of mTOR signalling components in drug resistance in ovarian cancer.

Helen Foster1, Helen M Coley, Anastasia Goumenou, George Pados, Amanda Harvey, Emmanouil Karteris.   

Abstract

BACKGROUND/AIM: A limitation to successful cancer chemotherapy treatments is the acquisition of drug resistance. In advanced-stage ovarian cancer, the mammalian target of rapamycin (mTOR) pathway is up-regulated, and inhibition of this pathway increases chemosensitivity in ovarian carcinoma cell lines. In this study, the expression of DEPTOR, mTOR, RICTOR, RAPTOR and S6 kinases were investigated in SKOV-3 and PEO1 parental and the paclitaxel-resistant (TaxR) SKOV-3TaxR and PEO1TaxR cell lines.
MATERIALS AND METHODS: RT-PCR, immunofluorescent analysis and Western blotting were carried out.
RESULTS: Quantitative RT-PCR revealed significant up-regulation of DEPTOR in both paclitaxel-resistant cell lines. SKOV-3TaxR exhibited down-regulation of RICTOR, RAPTOR and mTOR, whereas PEO1-TaxR showed down-regulation of RAPTOR and up-regulation of RICTOR and mTOR. Semi-quantitative RT-PCR analysis revealed marked changes in the expression of p70S6K splice variants mRNA in PEO1TaxR. Moreover, the phosphorylation status of p70S6K at Ser371 appears to be cell-type specific.
CONCLUSION: We hypothesize that mTOR signalling may play a role in mediating paclitaxel resistance in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944133

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy.

Authors:  Yongchao Zhao; Xiufang Xiong; Yi Sun
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

2.  The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone.

Authors:  Helen A Foster; Julie Davies; Ryan C Pink; Serife Turkcigdem; Anastasia Goumenou; David R Carter; Nigel J Saunders; Peter Thomas; Emmanouil Karteris
Journal:  J Steroid Biochem Mol Biol       Date:  2013-03-26       Impact factor: 4.292

3.  DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses.

Authors:  Sarah Bruneau; Hironao Nakayama; Craig B Woda; Evelyn A Flynn; David M Briscoe
Journal:  Blood       Date:  2013-07-23       Impact factor: 22.113

Review 4.  DEPTOR ubiquitination and destruction by SCF(β-TrCP).

Authors:  Zhiwei Wang; Jiateng Zhong; Daming Gao; Hiroyuki Inuzuka; Pengda Liu; Wenyi Wei
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-27       Impact factor: 4.310

5.  Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.

Authors:  Robert Riehle; Bhushan Pattni; Aditi Jhaveri; Abhijit Kulkarni; Ganesh Thakur; Alexei Degterev; Vladimir Torchilin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

Review 6.  Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.

Authors:  Yongchao Zhao; Yi Sun
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

Review 7.  An evolving role for DEPTOR in tumor development and progression.

Authors:  Zhiwei Wang; Jiateng Zhong; Hiroyuki Inuzuka; Daming Gao; Shavali Shaik; Fazlul H Sarkar; Wenyi Wei
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

8.  Placental DEPTOR as a stress sensor during pregnancy.

Authors:  Dionisis Mparmpakas; Elena Zachariades; Anastasia Goumenou; Yori Gidron; Emmanouil Karteris
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

9.  Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.

Authors:  B K Nayak; D Feliers; S Sudarshan; W E Friedrichs; R T Day; D D New; J P Fitzgerald; A Eid; T Denapoli; D J Parekh; Y Gorin; K Block
Journal:  Oncogene       Date:  2012-08-06       Impact factor: 9.867

10.  microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin.

Authors:  Zhongxian Wang; Zhou Ting; Ya Li; Gang Chen; Yunping Lu; Xing Hao
Journal:  Oncol Lett       Date:  2013-07-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.